SpringerLink
Log in

Pharmaceutical Company Payments to Clinical Practice Guideline Authors

  • Chapter
  • First Online:
Integrity of Scientific Research

  • 744 Accesses

Abstract

Internationally, efforts promoting greater transparency and improved management strategies for conflicts of interest (COI) have gained traction in healthcare settings. This particularly pertains to the development and use of clinical practice guidelines (CPG). Mounting evidence indicates that pharmaceutical industry payments to GPG authors and developers influence clinical recommendations, including drug selection, often to benefit commercial interests and at the expense of patients. To prevent undue influence of COI and develop trustworthy CPG, authors and develo** organizations should establish strict COI management policies, including full disclosure. Such policies should include details about the monetary values and funding sources of all payments and gifts from pharmaceutical companies. Authors and developers should refuse any payments or gifts while drafting CPG. CPG developers should establish clear and comprehensive COI definitions and create monitoring committees that implement COI policies, promote external review, and track COI declared by CPG authors using existing payment databases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 117.69
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 160.49
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 160.49
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

COI:

Conflicts of interest

CPG:

Clinical practice guidelines

GIN:

Guidelines International Network

NAM:

National Academy of Medicine

rhAPC:

Recombinant human activated protein C

USA:

United States of America

References

  1. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E (eds) (2011) Institute of medicine. Clinical practice guidelines we can trust. The National Academies Press, Washington, DC, 290 p

    Google Scholar 

  2. Lo B, Field MJ (eds) (2009) Institute of Medicine. Conflict of interest in medical research, education, and practice. The National Academies Press, Washington, DC, 436 p

    Google Scholar 

  3. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP, Guideline Panel Review Working Group (2013) Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ 347:f5535

    Article  PubMed  Google Scholar 

  4. Johnson L, Stricker RB (2009) Attorney general forces Infectious Diseases Society of America to redo Lyme guidelines due to flawed development process. J Med Ethics 35(5):283–288

    Article  CAS  PubMed  Google Scholar 

  5. Medicine AFABoI, Medicine A-AFACoP-ASoI, European Federation of Internal M (2002) Medical professionalism in the new millennium: a physician charter. Ann Intern Med 136(3):243–246

    Article  Google Scholar 

  6. Moynihan R (2008) Key opinion leaders: independent experts or drug representatives in disguise? BMJ 336(7658):1402–1403

    Article  PubMed  PubMed Central  Google Scholar 

  7. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D (2007) A national survey of physician-industry relationships. N Engl J Med 356(17):1742–1750

    Article  CAS  PubMed  Google Scholar 

  8. Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287(5):612–617

    Article  PubMed  Google Scholar 

  9. Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L (2006) Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychosom 75(3):154–160

    Article  PubMed  Google Scholar 

  10. Bindslev JB, Schroll J, Gotzsche PC, Lundh A (2013) Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. BMC Med Ethics 14:19

    Article  PubMed  PubMed Central  Google Scholar 

  11. Shnier A, Lexchin J, Romero M, Brown K (2016) Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase. BMC Health Serv Res 16(a):383

    Article  PubMed  PubMed Central  Google Scholar 

  12. Saito H, Ozaki A, Sawano T, Shimada Y, Tanimoto T (2019) Evaluation of pharmaceutical company payments and conflict of interest disclosures among oncology clinical practice guideline authors in Japan. JAMA Netw Open 2(4):e192834

    Article  PubMed  PubMed Central  Google Scholar 

  13. Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E et al (2019) Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. BMJ Open 9(2):e025864

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wilson JM (2009) Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96(4):151–157

    Article  CAS  PubMed  Google Scholar 

  15. Mullard A (2011) Mediator scandal rocks French medical community. Lancet 377(9769):890–892

    Article  PubMed  Google Scholar 

  16. Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T (2019) Payments from pharmaceutical companies to authors involved in the valsartan scandal in Japan. JAMA Netw Open 2(5):e193817

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pham-Kanter G (2014) Act II of the sunshine act. PLoS Med 11(11):e1001754

    Article  PubMed  PubMed Central  Google Scholar 

  18. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S (2020) Trends in industry payments to physicians in the United States from 2014 to 2018. JAMA 324(17):1785–1788

    Article  PubMed  PubMed Central  Google Scholar 

  19. Checketts JX, Sims MT, Vassar M (2017) Evaluating industry payments among dermatology clinical practice guidelines authors. JAMA Dermatol 153(12):1229–1235

    Article  PubMed  PubMed Central  Google Scholar 

  20. Goupil B, Balusson F, Naudet F, Esvan M, Bastian B, Chapron A et al (2019) Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ 367:l6015

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rickard E, Ozieranski P, Mulinari S (2019) Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK. Health Policy 123(12):1244–1250

    Article  PubMed  Google Scholar 

  22. Pokorny AMJ, Bero LA, Moynihan R, Mintzes BJ (2021) Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly-available disclosures. Intern Med J 51(11):1816–1824

    Article  PubMed  Google Scholar 

  23. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T (2021) Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. Int Urogynecol J 32(2):443–451

    Article  PubMed  Google Scholar 

  24. Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A et al (2021) Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017. Health Policy 125(3):320–326

    Article  PubMed  Google Scholar 

  25. Carlisle A, Bowers A, Wayant C, Meyer C, Vassar M (2018) Financial conflicts of interest among authors of urology clinical practice guidelines. Eur Urol 74(3):348–354

    Article  PubMed  Google Scholar 

  26. Stoll M, Hubenschmid L, Koch C, Lieb K (2020) Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016. BMJ Open 10(9):e037395

    Article  PubMed  PubMed Central  Google Scholar 

  27. Mulinari S, Martinon L, Jachiet P-A, Ozieranski P (2021) Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. Health Policy 125(7):915–922

    Article  PubMed  Google Scholar 

  28. Mitchell AP, Basch EM, Dusetzina SB (2016) Financial relationships with industry among National Comprehensive Cancer Network guideline authors. JAMA Oncol 2(12):1628–1631

    Article  PubMed  Google Scholar 

  29. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA (2016) Distribution and patterns of industry-related payments to oncologists in 2014. J Nat Cancer Inst 108(12):djw163

    Article  PubMed  PubMed Central  Google Scholar 

  30. Saleh RR, Majeed H, Tibau A, Booth CM, Amir E (2019) Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. Cancer 125(22):4069–4075

    Article  PubMed  Google Scholar 

  31. Ozaki A, Saito H, Onoue Y, Sawano T, Shimada Y, Somekawa Y et al (2019) Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis. BMJ Open 9(9):e028805

    Article  PubMed  PubMed Central  Google Scholar 

  32. Feng H, Wu P, Leger M (2016) Exploring the industry-dermatologist financial relationship: insight from the open payment data. JAMA Dermatol 152(12):1307–1313

    Article  PubMed  Google Scholar 

  33. Maruf M, Sidana A, Fleischman W, Brancato SJ, Purnell S, Agrawal S et al (2018) Financial relationships between urologists and industry: an analysis of open payments data. Urol Pract 5(3):180–186

    Article  Google Scholar 

  34. Horn J, Checketts JX, Jawhar O, Vassar M (2018) Evaluation of industry relationships among authors of otolaryngology clinical practice guidelines. JAMA Otolaryngol Head Neck Surg 144(3):194–201

    Article  PubMed  PubMed Central  Google Scholar 

  35. Pathak N, Fujiwara RJT, Mehra S (2018) Assessment of nonresearch industry payments to otolaryngologists in 2014 and 2015. Otolaryngol Head Neck Surg 158(6):1028–1034

    Article  PubMed  Google Scholar 

  36. Papanikolaou GN, Baltogianni MS, Contopoulos-Ioannidis DG, Haidich A-B, Giannakakis IA, Ioannidis JPA (2001) Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions. BMC Med Res Methodol 1(1):3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Taylor R, Giles J (2005) Cash interests taint drug advice. Nature 437(7062):1070–1071

    Article  CAS  PubMed  Google Scholar 

  38. Neuman J, Korenstein D, Ross JS, Keyhani S (2011) Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ 343:d5621

    Article  PubMed  PubMed Central  Google Scholar 

  39. World Health Organization (2014) WHO handbook for guideline development. WHO. https://apps.who.int/iris/handle/10665/145714. Accessed 4 May 2021

    Google Scholar 

  40. Schunemann HJ, Al-Ansary LA, Forland F, Kersten S, Komulainen J, Kopp IB et al (2015) Guidelines international network: principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med 163(7):548–553

    Article  PubMed  Google Scholar 

  41. Japanese Association of Medical Sciences (2017) Japanese Association of Medical Sciences COI management guidance on eligibility criteria for clinical practice guideline formulation. p 15. https://jams.med.or.jp/guideline/clinical_guidance_e.pdf. Accessed 4 May 2021

  42. Senoo Y, Saito H, Ozaki A, Sawano T, Shimada Y, Yamamoto K et al (2021) Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension. Medicine (Baltimore) 100(12):e24816

    Article  PubMed  Google Scholar 

  43. Murayama A, Ozaki A, Saito H, Sawano T, Shimada Y, Yamamoto K et al (2020) Pharmaceutical company payments to dermatology clinical practice guideline authors in Japan. PLoS One 15(10):e0239610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Saito H, Tani Y, Ozaki A, Sawano T, Shimada Y, Yamamoto K et al (2019) Financial ties between authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan. Clin Microbiol Infect 25(11):1304–1306

    Article  CAS  PubMed  Google Scholar 

  45. Nissen Steven E (2019) Can we trust the independence of cardiovascular guidelines? Circ Cardiovasc Qual Outcomes 12(12):e006225

    Article  CAS  PubMed  Google Scholar 

  46. Orlowski JP, Wateska L (1992) The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest 102(1):270–273

    Article  CAS  PubMed  Google Scholar 

  47. Nejstgaard CH, Bero L, Hrobjartsson A, Jorgensen AW, Jorgensen KJ, Le M et al (2020) Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ 371:m4234

    Article  PubMed  PubMed Central  Google Scholar 

  48. Steinbrook R (2007) Guidance for guidelines. N Engl J Med 356(4):331–333

    Article  CAS  PubMed  Google Scholar 

  49. Eichacker PQ, Natanson C, Danner RL (2006) Surviving sepsis — practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 355(16):1640–1642

    Article  CAS  PubMed  Google Scholar 

  50. McKee S (2009) Eisai/Pfizer’s Alzheimer’s battle with NICE comes to an end Online: Pharma Times Online [updated July 2]. pharmatimes.com/news/eisaipfizers_alzheimers_battle_with_nice_comes_to_an_end_984556. Accessed 4 May 2021

  51. Lenzer J (2013) Why we can’t trust clinical guidelines. BMJ 346:f3830

    Article  PubMed  Google Scholar 

  52. Lenzer J (2011) French guidelines are withdrawn after court finds potential bias among authors. BMJ 342:d4007

    Article  PubMed  Google Scholar 

  53. Jefferson AA, Pearson SD (2017) Conflict of interest in seminal hepatitis C virus and cholesterol management guidelines. JAMA Intern Med 177(3):352–357

    Article  PubMed  Google Scholar 

  54. Irwig MS, Kyinn M, Shefa MC (2018) Financial conflicts of interest among authors of Endocrine Society clinical practice guidelines. J Clin Endocrinol Metab 103(12):4333–4338

    Article  PubMed  Google Scholar 

  55. Wayant C, Walters C, Zaaza Z, Gilstrap C, Combs T, Crow H et al (2020) Evaluation of financial conflicts of interest among physician-authors of American College of Rheumatology clinical practice guidelines. Arthritis Rheumatol 72(9):1427–1434

    Article  PubMed  Google Scholar 

  56. Dudum R, Sajja A, Amdur RL, Choi BG (2019) Analysis of American College of Cardiology/American Heart Association guideline author self-disclosure compared with open payments industry disclosure. Circ Cardiovasc Qual Outcomes 12(12):e005613

    Article  PubMed  Google Scholar 

  57. Norris SL, Holmer HK, Burda BU, Ogden LA, Fu R (2012) Conflict of interest policies for organizations producing a large number of clinical practice guidelines. PLoS One 7(5):e37413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Morciano C, Basevi V, Faralli C, Hilton Boon M, Tonon S, Taruscio D (2016) Policies on conflicts of interest in health care guideline development: a cross-sectional analysis. PLoS One 11(11):e0166485

    Article  PubMed  PubMed Central  Google Scholar 

  59. DeJong C, Aguilar T, Tseng C-W, Lin GA, Boscardin WJ, Dudley RA (2016) Pharmaceutical industry–sponsored meals and physician prescribing patterns for medicare beneficiaries. JAMA Int Med 176(8):1114–1122

    Article  Google Scholar 

  60. International Committee of Medical Journal Editors (2019) Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals [Updated December 2019]. icmje.org/icmje-recommendations.pdf. Accessed 4 May 2021

  61. Booth CM, Detsky AS (2019) From the $80 hamburger to managing conflicts of interest with the pharmaceutical industry. BMJ 365:l1939

    Article  PubMed  Google Scholar 

  62. Miyata Y (2009) An internet survey of physicians’ attitude towards gifts from drug companies. Med Educ 40(2):95–104

    Google Scholar 

  63. Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS (2016) Association of Industry Payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Int Med 176(6):763–768

    Article  Google Scholar 

  64. Schünemann HJ, Osborne M, Moss J, Manthous C, Wagner G, Sicilian L et al (2009) An official American Thoracic Society policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med 180(6):564–580

    Article  PubMed  Google Scholar 

  65. Akl EA, El-Hachem P, Abou-Haidar H, Neumann I, Schunemann HJ, Guyatt GH (2014) Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study. J Clin Epidemiol 67(11):1222–1228

    Article  PubMed  Google Scholar 

  66. Norris SL, Holmer HK, Ogden LA, Burda BU, Fu R (2013) Conflicts of interest among authors of clinical practice guidelines for glycemic control in type 2 diabetes mellitus. PLoS One 8(10):e75284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Abdoul H, Perrey C, Tubach F, Amiel P, Durand-Zaleski I, Alberti C (2012) Non-financial conflicts of interest in academic grant evaluation: a qualitative study of multiple stakeholders in France. PLoS One 7(4):e35247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Traversy G, Barnieh L, Akl EA, Allan GM, Brouwers M, Ganache I et al (2021) Managing conflicts of interest in the development of health guidelines. CMAJ 193(2):E49–E54

    Article  PubMed  PubMed Central  Google Scholar 

  69. Spielmans GI, Parry PI (2010) From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. J Bioethic Inq 7(1):13–29

    Article  Google Scholar 

  70. Tibau A, Bedard PL, Srikanthan A, Ethier JL, Vera-Badillo FE, Templeton AJ et al (2015) Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. J Clin Oncol 33(1):100–106

    Article  PubMed  Google Scholar 

  71. Desai AP, Chengappa M, Go RS, Poonacha TK (2020) Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019. Cancer 126(16):3742–3749

    Article  PubMed  Google Scholar 

  72. Campsall P, Colizza K, Straus S, Stelfox HT (2016) Financial relationships between organizations that produce clinical practice guidelines and the biomedical industry: a cross-sectional study. PLoS Med 13(5):e1002029

    Article  PubMed  PubMed Central  Google Scholar 

  73. Sonis J, Chen OM (2020) Approval processes in evidence-based clinical practice guidelines sponsored by medical specialty societies. PLoS One 15(2):e0229004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Bero L (2017) Develo** reliable dietary guidelines. BMJ 359:j4845

    Article  PubMed  Google Scholar 

  75. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A (2021) Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan. Clin Microbiol Infect 28(3):460–462. https://doi.org/10.1016/j.cmi.2021.11.019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Keyhani S, Kim A, Mann M, Korenstein D (2011) A new independent authority is needed to issue National Health Care guidelines. Health Aff 30(2):256–265

    Article  Google Scholar 

  77. Andreatos N, Zacharioudakis IM, Zervou FN, Muhammed M, Mylonakis E (2017) Discrepancy between financial disclosures of authors of clinical practice guidelines and reports by industry. Medicine (Baltimore) 96(2):e5711

    Article  PubMed  Google Scholar 

  78. Graham SS, Majdik ZP, Clark D, Kessler MM, Hooker TB (2020) Relationships among commercial practices and author conflicts of interest in biomedical publishing. PLoS One 15(7):e0236166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Shekelle PG (2018) Clinical practice guidelines: what’s next? JAMA 320(8):757–758

    Article  PubMed  Google Scholar 

  80. Mendelson TB, Meltzer M, Campbell EG, Caplan AL, Kirkpatrick JN (2011) Conflicts of interest in cardiovascular clinical practice guidelines. Arch Intern Med 171(6):577–584

    Article  PubMed  Google Scholar 

  81. Combs TR, Scott J, Jorski A, Heavener T, Vassar M (2018) Evaluation of industry relationships among authors of clinical practice guidelines in gastroenterology. JAMA Intern Med 178(12):1711–1712

    Article  PubMed  PubMed Central  Google Scholar 

  82. Napierala H, Schäfer L, Schott G, Schurig N, Lempert T (2018) Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch. BMC Med Ethics 19(1):65

    Article  PubMed  PubMed Central  Google Scholar 

  83. Combs T, Tritz D, Ivy H, von Borstel D, Horn J, Vassar M (2019) Financial conflicts of interest among authors of clinical practice guidelines for routine screening mammography. J Am Coll Radiol 16(11):1598–1603

    Article  PubMed  Google Scholar 

  84. Wang Y-B, Wang Q, Zhao M-J, Da-Lin HE, Wang Y-Y (2020) Conflict of interest and economic evidence in Chinese clinical practice guidelines pub-lished in 2018: a survey. Yixue **nzhi Zazhi 30(2):139–58 (in Chinese)

    CAS  Google Scholar 

  85. Elder K, Turner KA, Cosgrove L, Lexchin J, Shnier A, Moore A et al (2020) Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. CMAJ 192(23):E617–EE25

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgement

We thank the Tansa (formerly known as the Waseda Chronicle) for collaborating on this issue in Japan, and Dr. Derek Hagman for his constructive opinions and professional language editing.

Conflicts of Interest

Anju Murayama, Drs Ozaki, and Tanimoto have several papers concerning conflicts of interest among Japanese and USA healthcare professionals. Drs Ozaki and Tanimoto report receiving personal fees from Medical Network Systems, MNES Inc., a dispensing pharmacy, outside the scope of the submitted work. Dr. Tanimoto reports personal fees from Bionics Co., Ltd., outside the scope of the submitted work. We report no other disclosures. The Medical Governance Research Institute is a non-profit organization creating the payment database (Money for Docs Database) in Japan that received donations from a dispensing pharmacy company, Ain Pharmacies and other private individuals.

Author information

Authors and Affiliations

  1. Medical Governance Research Institute, Tokyo, Japan

    Anju Murayama, Akihiko Ozaki & Tetsuya Tanimoto

  2. Tohoku University School of Medicine, Sendai, Miyagi, Japan

    Anju Murayama

  3. Department of Breast and Throid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan

    Akihiko Ozaki

  4. Department of Internal Medicine, Navitas Clinic, Kawasaki, Kanagawa, Japan

    Tetsuya Tanimoto

Authors
  1. Anju Murayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akihiko Ozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuya Tanimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hospital das Clinicas, University of Sao Paulo, Sao Paulo, São Paulo, Brazil

    Joel Faintuch

  2. Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA

    Salomão Faintuch

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Murayama, A., Ozaki, A., Tanimoto, T. (2022). Pharmaceutical Company Payments to Clinical Practice Guideline Authors. In: Faintuch, J., Faintuch, S. (eds) Integrity of Scientific Research. Springer, Cham. https://doi.org/10.1007/978-3-030-99680-2_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-99680-2_45

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-99679-6

  • Online ISBN: 978-3-030-99680-2

  • eBook Packages: Social SciencesSocial Sciences (R0)

Publish with us

Policies and ethics

Search

Navigation